AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03035084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule
Study NCT03903614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SML
Description: SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
Study NCT03903614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
Study NCT02672891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: condom balloon catheter
Description: The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed.
Study NCT00143130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin
Study NCT04593238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic paste
Description: Metronidazole and Ciprofloxacin
Study NCT04593238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
Study NCT05967858 — intervention group
Intervention type: OTHER
Intervention: observation
Description: no intervention
Study NCT00461019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation and activation of the vagus nerve stimulator
Description: Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
Study NCT01605448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8 weekly classes of meditation/yoga
Study NCT03486574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positive result from pathological test
Description: Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
Study NCT01296815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
Study NCT03574103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction only
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
Study NCT03574103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus TRF morning
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
Study NCT03574103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus TRF night
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
Study NCT00909961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT01149759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
Study NCT02132559 — intervention group
Intervention type: DRUG
Intervention: DHEA
Study NCT00201149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered Counseling
Description: To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
Study NCT00936182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole daily for 30 days
Study NCT04229173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample, cerebrospinal fluid (optional)
Description: blood sample, cerebrospinal fluid
Study NCT04229173 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluations about motor abilities, depression, cognition and lifestyle
Description: Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
Study NCT04229173 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation about depression cognition
Description: Evaluations about depression (BDI scale), cognition (MoCA scale)
Study NCT00642278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
Study NCT00642278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
Study NCT00642278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
Study NCT00642278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
Study NCT00642278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
Study NCT03661697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face.
Study NCT03661697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face.
Study NCT03661697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Skin Care Regimen
Description: Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
Study NCT03661697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Skin Care Regimen
Description: Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
Study NCT00936182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole daily for 30 days
Study NCT03661697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera
Description: cosmeceutical serum applied to face daily for 12 weeks
Study NCT01025453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus and Sorafenib
Description: Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
Study NCT00792935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
Study NCT00792935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
Study NCT00792935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
Study NCT00792935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
Study NCT01059344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamin
Description: 4.8g/day, 800 mg tablets
Study NCT02771574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyo avexitide
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
Study NCT02771574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liq avexitide
Description: Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
Study NCT02382874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of AD-MSC to the patients with FSGS
Study NCT01133756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
Study NCT01133756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
Study NCT01133756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
Study NCT01133756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
Study NCT01133756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
Study NCT03620292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
Study NCT03620292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared (NIR) fluorescence imaging
Description: Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
Study NCT00338806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for prevention with adolescents
Description: Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
Study NCT00338806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational clinical monitoring
Description: Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
Study NCT00571051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: 8 week course in mindfulness training
Study NCT00311090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux sodium
Description: 0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection
Study NCT00311090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idraparinux sodium
Description: 0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection
Study NCT00311090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin
Description: 100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes
Study NCT00311090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Avidin)
Description: Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes
Study NCT00311090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Avidin)
Description: Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes
Study NCT02186886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab
Description: Physiological Intermolecular Modification Spectroscopy
Study NCT03283891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention - humanistic nursing practice
Description: Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor
Study NCT02952430 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
Study NCT00820963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00820963 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Patients undergo hypofractionated radiotherapy
Study NCT03403660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non White coat
Description: Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
Study NCT03501069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 capsules.
Study NCT00820963 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo standard radiotherapy
Study NCT01737021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-education
Description: The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
Study NCT04540003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to School Based Health Centre
Description: The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
Study NCT03916341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC with nicotine
Description: Use an EC with nicotine for up to 30 minutes
Study NCT03140046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photorefractive keratectomy (PRK)
Description: The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG).
Study NCT05634837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support System counseling
Description: Decision Support System counseling to improve diet and lifestyle in pregnancy
Study NCT05634837 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard nutritional counseling
Description: Counseling to improve diet and lifestyle in pregnancy
Study NCT00893763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-intubation CHX
Description: Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
Study NCT00893763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
Study NCT01430364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOSS LIM implantation
Description: BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
Study NCT01430364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOSS Lim
Study NCT01430364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CarloS
Study NCT03501069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418 Matching Placebo
Description: TAK-418 matching placebo capsules.
Study NCT03916341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC without nicotine
Description: Use an EC without nicotine for up to 30 minutes
Study NCT03916341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: sham control
Study NCT03916341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TC with nicotine (own brand)
Description: smoke a TC
Study NCT03916341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: research TC with very low level nicotine
Description: smoke a research TC with very low level nicotine
Study NCT03791996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cranioplasty
Description: Subjects undergoing cranioplasty beyond 3 months after craniectomy.
Study NCT01356524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Additional vaginal progesterone
Description: The progesterone dose will be raised from 200 mg daily to 300 mg daily
Study NCT02610608 — intervention group
Intervention type: OTHER
Intervention: ovarian stimulation
Description: evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
Study NCT04062396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eurosets REMOWELL 2 oxygenator
Description: The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
Study NCT04062396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LivaNova INSPIRE oxygenator
Description: INSPIRE oxygenator has no filtration system for extracavitary inlet
Study NCT02031185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitBit only
Description: Participants will use the FitBit device
Study NCT02031185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitBit and Text Messages
Description: Participants will use the FitBit device and receive daily affective text messages
Study NCT02022800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET 18FDOPA
Description: contribution of PET 18FDOPAimagery in high level glioma diagnosis
Study NCT04653506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
Study NCT04653506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
Study NCT02427139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANSiStim
Description: ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
Study NCT02269813 — intervention group
Intervention type: OTHER
Intervention: MammaPrint
Study NCT03081013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social information
Description: Social comparison information will be provided to the study participants weekly via SMS